Evidence map›Paper›PMID 32586403›Full record

ArticleStem cell research & therapy2020

Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with

P Stephen Patrick, Krishna K Kolluri, May Zaw Thin, Adam Edwards, Elizabeth K Sage, Tom Sanderson, Benjamin D Weil, John C Dickson, Mark F Lythgoe, Mark Lowdell and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The role of stem cells in precision medicine: next-generation cancer treatment.Journal of the Egyptian National Cancer Institute · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Evaluation of differentScientific reports · 2022
    Article
  18. Review
  19. Article
  20. Direct Cell Radiolabeling forChemical reviews · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

P Stephen PatrickCentre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, UK. peter.patrick@ucl.ac.uk.ORCID 0000-0002-7155-1729
Krishna K KolluriLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, UK.
May Zaw ThinCentre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, UK.
Adam EdwardsLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, UK.
Elizabeth K SageLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, UK.
Tom SandersonInstitute of Nuclear Medicine, University College London, London, UK.
Benjamin D WeilCentre for Cell, Gene & Tissue Therapeutics, Royal Free Hospital, London, UK.
John C DicksonInstitute of Nuclear Medicine, University College London, London, UK.
Mark F LythgoeCentre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, UK.
Mark LowdellCentre for Cell, Gene & Tissue Therapeutics, Royal Free Hospital, London, UK.
Sam M JanesLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, UK.
Tammy L KalberCentre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, UK. t.kalber@ucl.ac.uk.
University College London · GBThe Royal Free Hospital · GBAdvanced Imaging Research (United States) · USThe London College · GB

Funding

British Heart Foundation FS/15/33/31608Medical Research Council MR/K026739/1Medical Research Council MR/M015831/1Medical Research Council MR/R026416/1Wellcome TrustWellcome Trust WT107963AIA
6 · The paper itself

Abstract

backgroundMSCTRAIL is a cell-based therapy consisting of human allogeneic umbilical cord-derived MSCs genetically modified to express the anti-cancer protein TRAIL. Though cell-based therapies are typically designed with a target tissue in mind, delivery is rarely assessed due to a lack of translatable non-invasive imaging approaches. In this preclinical study, we demonstrate

methodsMSCTRAIL were radiolabelled with

resultsMSCTRAIL retained the therapeutic efficacy and MSC phenotype in vitro at labelling amounts up to and above those required for clinical imaging. The effect of

conclusions

Indexed as

Lung NeoplasmsPositron Emission Tomography Computed TomographyHumansLungOxyquinolineTissue DistributionOxyquinoline89Zr-oxineCell therapyCell trackingCord-derived MSCsLung cancerPET-CTTRAIL

Identifiers

PMID32586403
PMCPMC7318529
OpenAlexW3037608869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.